tbuckley/cabot-search huggingface dataset:
NI-22 * NON-ENHANCING TUMOR RESPONSE USING QUANTITATIVE T2 MAPS PREDICTS SURVIVAL IN GLIOBLASTOMA TREATED WITH BEVACIZUMAB
Authors: B. Ellingson, W. Pope, P. Nghiemphu, A. Lai, T. Cloughesy
Journal: Neuro-Oncology (2014)

BACKGROUND: Malignant gliomas are known to contain proportions of both neovascularized and infiltrative, non-enhancing tumor (NET). Additionally, a substantial proportion of treated tumors can have NET progression prior to contrast enhancement. There remains significant need for objective evaluation of NET; however, there remains much discrepancy and controversy behind the value of NET evaluation. We hypothesize that T2 relaxometry may be useful for objectively defining NET tissue using a specific range of T2 values and that volumetric changes in NET after therapy can predict survival. METHODS: Effective T2 maps were calculated from axial, dual echo, turbo spin echo images in 50 GBM patients at a single time point and a separate cohort of 24 GBM patients before and after bevacizumab. Tissue-specific T2eff measurements were obtained for normal white matter, NET, edema, and necrosis. NET was defined by a range of T2eff values with a highest sensitivity and specificity. The change in NET volume before and after bevacizumab was used to predict PFS and OS. RESULTS: ROC analysis demonstrated better delineation between tissue types at 3T compared with 1.5T (P < 0.05). A threshold of 125ms can delineate NET from NAWM with 96% sensitivity and 97% specificity at 1.5T and 94% sensitivity and 97% specificity at 3T. A threshold of 250ms can delineate NET from edema with a 91% sensitivity and 71% specificity at 1.5T and 98% sensitivity and 75% specificity at 3T. A decrease in the volume of NET (125ms< T2eff < 250ms) before and after bevacizumab in recurrent GBM was a significant predictor of OS9 (AUC = 0.87, P = 0.002) and PFS6 (AUC = 0.78, P = 0.022), and a decrease greater than 50% stratified TTP (Log-rank, P = 0.0141) and OS (Log-rank, P = 0.0205). CONCLUSION: Objectively defining NET tissue using T2eff maps allows for quantitative evaluation of NET response. This approach may be useful for defining NET response and progression in clinical trials.
Randomized Trial of Adjuvant Human Interferon Gamma Versus Observation in High-Risk Cutaneous Melanoma: a Southwest Oncology Group Study
Authors: F. L. Meyskens, K. J. Kopecky, C. W. Taylor, R. D. Noyes, R. J. Tuthill, E. M. Hersh, L. G. Feun, J. H. Doroshow, L. E. Flaherty, V. K. Sondak
Journal: JNCI Journal of the National Cancer Institute (1995)

Journal Article Randomized Trial of Adjuvant Human Interferon Gamma Versus Observation in High-Risk Cutaneous Melanoma: a Southwest Oncology Group Study Get access Frank L. Meyskens, Jr., Frank L. Meyskens, Jr. University of CaliforniaIrvine Search for other works by this author on: Oxford Academic PubMed Google Scholar Kenneth J. Kopecky, Kenneth J. Kopecky Southwest Oncology Group Statistical CenterSeattle, WA Search for other works by this author on: Oxford Academic PubMed Google Scholar Charles W. Taylor, Charles W. Taylor University of Arizona Cancer CenterTucson Search for other works by this author on: Oxford Academic PubMed Google Scholar R. Dirk Noyes, R. Dirk Noyes University of Utah Medical CenterSalt Lake City Search for other works by this author on: Oxford Academic PubMed Google Scholar Ralph J. Tuthill, Ralph J. Tuthill Cleveland Clinic FoundationOH Search for other works by this author on: Oxford Academic PubMed Google Scholar Evan M. Hersh, Evan M. Hersh University of Arizona Cancer CenterTucson Search for other works by this author on: Oxford Academic PubMed Google Scholar Lynn G. Feun, Lynn G. Feun University of Miami School of MedicineFL Search for other works by this author on: Oxford Academic PubMed Google Scholar James H. Doroshow, James H. Doroshow City of Hope National Medical CenterDuarte, CA Search for other works by this author on: Oxford Academic PubMed Google Scholar Lawrence E. Flaherty, Lawrence E. Flaherty Wayne State University Medical CenterDetroit, MI Search for other works by this author on: Oxford Academic PubMed Google Scholar Vernon K. Sondak Vernon K. Sondak University of Michigan Medical CenterAnn Arbor Vemon K. Sondak, M.D., 2920 Taubman Center, 1500 East Medical Center Dr., Ann Arbor, MI 48109-0331. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 87, Issue 22, 15 November 1995, Pages 1710–1713, https://doi.org/10.1093/jnci/87.22.1710 Published: 15 November 1995 Article history Received: 06 April 1995 Revision received: 15 August 1995 Accepted: 15 August 1995 Published: 15 November 1995
Attenuated Rubella Virus
Authors: Paul D. Parkman, Harry M. Meyer, Ruth L. Kirschstein, Hope E. Hopps
Journal: New England Journal of Medicine (1966)

ALTHOUGH the need for an effective, safe rubella-virus vaccine has long been recognized it was not until 1962, when the virus was isolated and propagated in the laboratory,1 , 2 that development of a vaccine became theoretically possible. Interest in preventing rubella and associated teratogenesis was further intensified by observations made during the recent epidemic of 1963–1964. Although our early attempts to produce a killed-virus vaccine were unsuccessful, development of a live-virus vaccine seemed feasible, and approaches that had been used to attenuate other viruses were explored. In attempts to produce attenuation rubella viruses were subjected to protracted passage in tissue cultures. . . .
THU0283 Serological Prevalence of Hepatitis B Virus Infection among Patients with Different Rheumatic Disease: A Prospective Study: Table 1
Authors: G. Vukatana, N. Gamal, M. Trevisani, C. Cursaro, P. Andreone, N. Malavolta
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Reactivation of HBV infection is a serious problem in the setting of immunosuppression. <h3>Objectives</h3> This prospective study was designed to determine the prevalence of anti-HBc and HBsAg among consecutive patients with different rheumatic diseases referred to an outpatient rheumatology clinic in Italy between December 2011 and January 2014. <h3>Methods</h3> We enrolled 540 patients (394 female; mean age 55±14.2 yrs) with various rheumatic diseases. All were tested for anti-HBc as well as for HBsAg and HBV-DNA if anti-HBc positive. <h3>Results</h3> Among the 540 patients, anti-HBc was detected in 101/540 (19%). HBsAg was positive in 8/540 (1.5%) with a positive HBV-DNA in 2 patients (330 and 9.092 UI/ml, respectively), not detected in 4 and not available in the other two. Prevalence of anti-HBc was significantly higher in males 37/146 <i>vs</i> 64/394 in females; p=0.018. Non-Italians showed higher prevalence of anti-HBc compared to Italians (23/99 <i>vs</i> 76/441 respectively, p=0.202). 16/101 (16%) anti-HBc-positive patients have received biological treatment (alone or in association with disease-modifying antirheumatic drugs) ± steroids for an average of 7.5 years but none developed HBV reactivation. The prevalence of anti-HBc in different rheumatic diseases is analyzed in the table 1. <h3>Conclusions</h3> About one fifth of rheumatic patients are anti-HBc positive which showed higher prevalence in males. Screening for a resolved or active HBV infection is mandatory for all patients with rheumatic diseases especially if candidates for an immunosuppressive therapy. The potential risk of HBV reactivation in such setting is low. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5467
Bacteriuria and Pyelonephritis of Pregnancy
Authors: Alan L. Kaitz, Elizabeth W. Hodder
Journal: New England Journal of Medicine (1961)

Pyelonephritis is the most frequent medi-*• cal cause of hospitalization during pregnancy.1 Physiologic changes within the urinary tract that may predispose to pyelonephritis occur in all pregnant women.2 It is not clear, however, why acute symptomatic pyelonephritis develops in some and not in others. If it were possible to detect the cases in which pyelonephritis of pregnancy is destined to develop, preventive treatment could be given to eliminate the morbidity of acute infections during pregnancy and the hazards of any possible late complications.Kass3 has reported that about 6 or 7 per cent of pregnant women attending the Boston City . . .
OT2-07-02: SWOG S0927: A Randomized Double Blind Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor (AI)-Induced Musculoskeletal Pain in Women with Early Stage Breast Cancer.
Authors: DL Hershman, JM Unger, KD Crew, CM Moinpour, LM Minasian, L Hansen, DL Lew, K Kaberle, JL Wade, FL Meyskens
Journal: Cancer Research (2011)

Abstract Background: Despite the well-proven efficacy of aromatase inhibitors(AIs) for the treatment of hormone-sensitive breast cancer, a significant number of women suffer from musculoskeletal side-effects which can result in early discontinuation of this important medication. Given the proposed anti-inflammatory effects of omega-3-fatty acid and the paucity of therapeutic options for AI-induced arthralgia, it is therefore reasonable to test the efficacy of omega-3-fatty acid in women with breast cancer who have developed moderate to severe joint symptoms after initiating AIs. Specific aims: To assess if omega-3-fatty acid as compared to placebo causes a reduction in worst joint pain/stiffness in women with AI-associated arthralgias at 12weeks as measured by the modified Brief Pain Inventory (BPI). Additional measures will include the WOMAC, M-SACRAH, FACT-ES and global rating of change, which will be assessed at baseline, 6, 12 and 24 weeks. We will evaluate fasting lipids, hormone levels, serum inflammatory markers (TNF, IL2, CRP), and markers of joint destruction (CTX-II) at baseline, 12 and 24 weeks. Eligibility criteria:Pts. must have histologically-confirmed stages I-III breast cancer, with no evidence of metastatic disease and undergone definitive breast cancer surgery. Pts must be post-menopausal and currently be taking a third-generation AI —anastrazole(Arimidex®), letrozole (Femara®), or exemestane (Aromasin®) for at least the previous 90 days prior to registration with plans to continue for at least an additional 180 days after registration.The patient must have a worse joint pain/stiffness score of 5 or greater on the 10-point scale of the BPI which started or increased after initiation of AI. Pts must not have taken omega-3-fatty acid supplements within the past 3 months prior to registration.Pts will be randomized to receive 6 capsules daily (at 1,000 mg each; ∼600mg combination of ethyl esters EPA/DHA) of omega-3-fattyacid or matching placebo daily for 24 weeks. Statistical methods:We stipulate an alpha=.05 two-sided test, with an estimated 5% non-adherenceand 20% dropout rate at the primary endpoint evaluation time of 12 weeks after randomization. For a two point difference in worst joint pain/stiffness and a 3.5 point SD at 12 weeks, 222 eligible patients would be required for 90% power under a two-arm normal design. To allow ineligibility rate of 10%, 246 total pts will be enrolled. The study should be activated September 2011. Funding: Supported by National Cancer Institute grant CA037429 Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr OT2-07-02.
Abstract 2929: MAP/MEK pathway inhibitors reduce cell viability of canine hemangiosarcoma primary cells
Authors: Nicholas Andersen, Elissa Boguslawski, Roe Froman, Alexander Blanski, Rida Zaida, Josh Smith, Karl Dykema, Kyle Furge, Nicholas Duesbery
Journal: Cancer Research (2011)

Abstract Angiosarcoma is a rare endothelial derived soft-tissue tumor with an estimated incidence of 0.2/100,000 persons/year. Current treatment regimes include surgical resection followed by chemotherapy. Even after treatment, reoccurrence is likely and usually fatal. The canine equivalent of angiosarcoma, hemangiosarcoma (HSA), is a relatively common canine endothelial neoplasm with an overall incidence of 24/100,000. In addition, canine HSA is more prevalent in specific breeds suggesting a genetic component. Similar to human angiosarcoma, HSA present as two basic forms: visceral (spleen or cardiac) and dermal. Furthermore, canine HSA occur spontaneously making canine HSA a relevant model system to study human angiosarcoma. Interestingly, MEK/MAPK signaling cascade is activated in Kaposi's Sarcoma, another human endothelial derived cancer. We hypothesize that the MEK/MAPK signaling cascade is vital for HSA and angiosarcoma growth and survival. We performed expression analysis supplemented by small molecule inhibitor studies utilizing canine primary cell isolates derived from visceral and dermal HSA. MAPK pathway expression signatures are elevated in HSA primary isolates compared to proliferating endothelial cells. Consistent with mRNA expression studies, ERK2 is constitutively phosphorylated in serum starved conditions. In addition, HSA cell viability is reduced by the MEK1/2 inhibitor CI-1040 compared to isolated canine endothelial cells. Other inhibitors targeting tyrosine kinase receptors (Sorafenib, EGFR Inhibitor, and SU11652) also decrease HSA cell viability. We conclude a network of tyrosine kinase receptors constitutively activate the MEK/MAPK signaling pathway in HSA. This work provides insights in the etiology and therapeutic potential for targeting both canine HSA and angiosarcoma. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2929. doi:10.1158/1538-7445.AM2011-2929
Regulatory Approval and Technological Advances Raise Hopes for Photodynamic Therapy
Authors: N. S. Larsen
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Regulatory Approval and Technological Advances Raise Hopes for Photodynamic Therapy Get access Natalie S. Larsen Natalie S. Larsen Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 18, 15 September 1993, Pages 1453–1454, https://doi.org/10.1093/jnci/85.18.1453 Published: 15 September 1993
A Diverse Induction of Apoptosis by Trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2 + /ER-) Breast Cancer Cells
Authors: H. Atmaca, E. Bozkurt, S. Uzunoglu, R. Uslu, B. Karaca
Journal: Annals of Oncology (2013)
Differences between Men and Women in the Rate of Use of Hip and Knee Arthroplasty
Authors: Gillian A. Hawker, James G. Wright, Peter C. Coyte, J. Ivan Williams, Bart Harvey, Richard Glazier, Elizabeth M. Badley
Journal: New England Journal of Medicine (2000)

Previous studies suggest that, for some conditions, women receive fewer health care interventions than men. We estimated the potential need for arthroplasty and the willingness to undergo the procedure in both men and women and examined whether there were differences between the sexes.
PMO-173 District general hospital networks can provide safe and effective hepatitis C treatment: results of a 4-year audit: Abstract PMO-173 Table 1
Authors: T Hydes, H Allen, S Al-Shamma, C Hovell, N Sharer, E Williams
Journal: Gut (2012)

<h3>Introduction</h3> Chronic Hepatitis C (CHC) treatment is well described in the context of Randomised Controlled Trials (RCTs).<sup>1</sup> Whether these findings can be extrapolated to treatment programmes delivered by nurse specialists working in District General Hospitals (DGHs) is unclear. <h3>Methods</h3> The Dorset Viral Hepatitis Network has a catchment area of 750 000 people. Patients are assessed and treated in three DGHs by a team of nurse specialists working under the supervision of four lead clinicians. Between January 2007 and January 2011 standard of care for CHC treatment was Ribavirin and Pegylated Interferon α2a given for 24 weeks (G2/3 patients) to 48 weeks (G1/4). A retrospective analysis of the network9s reference database was undertaken focusing on treatment naïve patients. <h3>Results</h3> In total 207 treatment naïve patients received antiviral therapy. Mean age at time of treatment was 43 years (20–66); 74% (154) were male and 67% (139) acquired CHC through injection drug use. G1 patients represented 49% (102) of the cohort; 3% (6) were Hepatitis B/HIV co-infected and 95% (196) were Caucasian. A clinical or histological diagnosis of cirrhosis was present in 8% (16). In total 12% (24) moved out of area or were lost to follow-up within 24 weeks of completing treatment. Based on intention to treat, Sustained Virological Response rates (undetectable HCV RNA in serum 24 weeks post treatment) were comparable to those derived from RCT<sup>1</sup> data (Abstract PMO-173 table 1). Non-response was observed in 11% (11/102), 5% (5/98) and 14% (1/7) of G1, G2/3 and G4 patients respectively. Breakthrough or relapse was observed in 18% (18/102), 13% (13/98) and 14% (1/7) of G1, G2/3 and G4 patients respectively. Overall 1% (3) of patients discontinued treatment as a result of a laboratory abnormality and 12% (24) because of other medical complications or side effect intolerance. These proportions are comparable to those observed in RCTs (p=0.735, p=0.146). <h3>Conclusion</h3> Specialist nurses supported by a network of DGHs can deliver a high quality Hepatitis C service across a broad geographical area. These findings are encouraging when considering a move towards community based CHC management. <h3>Competing interests</h3> None declared. <h3>Reference</h3> 1. <b>Fried MW</b>, Shiffman ML, Reddy KR, <i>et al.</i> Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. <i>New Engl J Med</i> 2002;<b>347</b>:975–82.
FRI0482-HPR Clinical tools association in knee osteoarthritis patients. Objective measures vs subjective measures:
Authors: L. Martin-Martin, C. Magro-Checa, C. Valenza, Y. Castellote-Caballero, J.C. Caracuel-Martinez, M. Fajardo-Rodriguez, G. Valenza
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Knee osteoarthritis (OA) is the most common disease of joints in older adults around the world. It is a chronic condition associated with pain and reduction in physical function, leading to a negative impact on the physical and psychosocial well-being of patients. Therefore, different instruments have been developed to evaluate the impact of OA on functioning and quality of life of patients<sup>2</sup> <h3>Objectives</h3> To determine the association between subjective and objectivemeasuring tools of knee osteoarthritis patients enrolled in Spanish primary care <h3>Methods</h3> 120 patients with radiologically confirmed knee osteoarthritis. The following scores were calculated and recorded for logistic regression analysis: Visual Analogue Scale (VAS) for pain, Western Ontario and McMaster Osteoarthritis Index (WOMAC) for functional status, and EQ-5D for Health related quality of life, radiographic severity measured by Kellgren-Lawrence grade (K/L), age and Body Mass Index (BMI) <h3>Results</h3> An 80% of the sample were women, mean (SD) age 64,11 (10,361) and BMI 31,40 kg/m<sup>2</sup> (5,3). Radiographic severity mean (SD) was 2, 63 (0,685) and 75% had more affected joints besides knee. Mean (SD) standardized tools scores were: EVA 6,46 (2,3 SD); EQ-5D 0,58 (0,23); EQ-5D VAS 56,6 (16,9); WOMAC pain 8,97 (3,7); WOMAC stiffness 3 (2); WOMAC function 29,5 (12,8) and WOMAC global 41,5 (16,86). No significant association between radiographic severity and subjective health statewas finding. Age and BMI were not correlated either, although older people had worse radiologic severity (p=0,002), and fattest people had more pain and stiffness measured by WOMAC index <h3>Conclusions</h3> This sample shows that radiographic severity does not match with knee symptomatology as other studies have previously assert. Just WOMAC index was correlated with objective measures. Further studies could inquire why higher BMI is associated with worse stiffness and pain scores in WOMAC index but does not impact in people function <h3>References</h3> Tsonga T, Kapetanakis S, Papadopoulos C, Papathanasiou J, Mourgias N, Georgiou N Open Orthop J Xie F, Pullenayegum EM, Li SC, Hopkins R, Thumboo J, Lo NN Value Health <h3>Disclosure of Interest</h3> None Declared
SC-13 * ID1-CULLIN3 AXIS REGULATES STEM CELL SIGNALING IN GLIOMA
Authors: X. Jin, X. Jin, H. Kim, J. Rich
Journal: Neuro-Oncology (2014)

Glioblastomas are highly lethal cancers that display cellular hierarchies with glioma stem cells (GSCs) at the apex. Targeting GSCs may provide improved tumor control, underscoring the need for improved understanding of their underlying biology. Inhibitor of differentiation 1 (ID1) promotes gliomagenesis through stimulation of GSC growth. We now report that ID1 controls GSCs through suppression of the E3 ligase, Cullin3. Cullin3 feedback suppression of ID1 simultaneously activates ligand-independent WNT and SHH signaling by increasing Dvl2 and Gli2 levels, respectively. Further, Cullin3 suppresses BMP signaling by attenuating BMPR2 through WNT-b-catenin-driven miR-17/-20a induction. The clinical relevance of these findings is supported by an in silico association of the ID1High/Cullin3Low gene expression signature in glioblastomas with the activation of multiple stem cell pathways. Simultaneous targeting of these core GSC pathways enhanced survival of GSC-bearing mice, supporting translation into a novel targeted therapy. Taken together, these findings suggest that Cullin3 represents a common signaling node controlling the activity of multiple essential GSC pathways mediated by ID1.